SEC Form 4 · accession 0001543077-17-000002
ARGOS THERAPEUTICS INC · ARGS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jeffrey D Abbey
Officer — Chief Executive Officer · Director
Period of report
Aug 30, 2017
Accepted (ET)
Aug 31, 2017 · 6:29 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001105533
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Aug 30, 2017 | A | 622,685 | $0.00 | A | 749,735 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The shares are subject to a lapsing right of repurchase by the issuer, which shall lapse as to 311,342 sharse on January 2, 2018, and with respect to the remaining 311,343 shares on January 9, 2018, subject to the Reporting Person continuing to be an employee of the issuer through each such date.